GVP Module XVI: Pregnancy Prevention Programmes in the EU — Risk Minimisation and Member State Implementation

Introduction

Pregnancy prevention programmes (PPPs) are among the most structured forms of additional risk minimisation used for medicinal products with embryo-fetal risks. They are not simply patient information programmes. A PPP can combine educational measures with interventions intended to prevent exposure during pregnancy, and its design has to follow the characteristics of the medicinal product, the nature of the risk, the treatment population and the clinical context.

The EU framework has evolved. GVP Module XVI Revision 3 became legally effective on 6 August 2024. GVP Module XVI Addendum I, specifically addressing risk minimisation for medicinal products with embryo-fetal risks, became legally effective on 29 August 2025. EMA describes Addendum I as applicable to new marketing-authorisation applications, new risk-minimisation measures and new effectiveness studies within its scope. The current GVP page also lists Addendum II on effectiveness evaluation as legally effective from 6 August 2024. 1

The central practical issue is that an EU-level risk-minimisation framework does not necessarily produce an identical operational programme in every Member State. The underlying safety objective may be common while prescribing pathways, documentation, testing arrangements, dispensing controls, educational materials and digital or paper workflows differ nationally.

This article therefore separates three questions:

1. What does the current EU GVP framework require or recommend for embryo-fetal risk minimisation?
2. When is a PPP appropriate, and what elements can it contain?
3. How can the same safety objective be implemented differently in Member States?

The purpose is not to create a single model that every country must follow. It is to provide a framework for understanding the regulatory objective, the control architecture and the national implementation layer.

1. The Regulatory Starting Point

Risk minimisation begins with the safety concern, not with the preferred control mechanism.

For a medicinal product with an embryo-fetal risk, the first question is how exposure can lead to harm and whether exposure during pregnancy can be prevented, reduced or managed. The intervention should then be selected according to the risk and the clinical circumstances.

GVP Module XVI establishes the general risk-minimisation framework. Addendum I provides specific guidance for medicinal products with embryo-fetal risks. The two should therefore be read together rather than treating the Addendum as a standalone operational manual.

The distinction between routine and additional risk minimisation remains important. Routine measures such as product information, labelling and standard prescribing controls may address part of the risk. Additional measures are considered where routine measures are insufficient and a further intervention is justified.

2. Embryo-Fetal Risk Is Not Automatically a PPP Case

The existence of a teratogenic or embryo-fetal risk does not mean that every product requires a full PPP.

The risk-minimisation approach should be proportionate to the risk and capable of addressing the mechanism by which exposure could cause harm. Depending on the circumstances, measures can range from strengthened warnings and counselling to more structured controls around prescribing, pregnancy testing, contraception, specialist supervision or dispensing.

This is an important regulatory principle. A PPP is a risk-minimisation intervention, not a default label applied to every medicine with a reproductive safety concern.

3. What a PPP Is Intended to Achieve

The practical objective of a PPP is to prevent or minimise embryo-fetal exposure to a medicinal product where exposure presents a clinically important risk.

The objective should be translated into operational actions. Depending on the product, these may include:

• identifying people who can become pregnant;
• ensuring that treatment is not started during pregnancy when contraindicated;
• ensuring appropriate contraception where required;
• performing pregnancy testing at defined points;
• providing risk counselling;
• ensuring prescribers understand the relevant restrictions;
• documenting that required conditions have been fulfilled;
• controlling prescribing or dispensing where justified;
• providing patient-facing educational material; and
• establishing a pathway for action if pregnancy occurs or exposure is suspected.

The programme should therefore be designed as a control system rather than as a collection of leaflets.

4. The PPP as a Control Architecture

A useful way to conceptualise a PPP is as a chain of controls:

Embryo-fetal risk
        ↓
Risk-minimisation objective
        ↓
Who is at risk of exposure?
        ↓
What must happen before treatment?
        ↓
What must happen during treatment?
        ↓
What must happen after treatment?
        ↓
How is compliance documented?
        ↓
How is dispensing controlled where necessary?
        ↓
How is effectiveness assessed?

Each control should have a purpose. Adding a form, card or test without identifying the safety decision it supports can create administrative burden without materially improving risk control.

5. The Importance of the Treatment Context

The same pharmacological hazard can require different operational controls depending on the indication and population.

A product used for a chronic condition may require repeated reassessment and repeated pregnancy-prevention controls. A short treatment course may require a different timing strategy. A medicine used only under specialist supervision may have a different control architecture from one prescribed routinely in primary care.

The programme should therefore be designed around the actual treatment pathway.

6. Identifying People Who Can Become Pregnant

A PPP should define the population to whom its pregnancy-prevention conditions apply in accordance with the applicable product-specific and regulatory framework.

The assessment should not be reduced to an assumption based solely on age, marital status or reported sexual activity. Clinical circumstances and the product's authorised conditions must be considered.

The purpose of identifying the relevant population is to apply the controls to people for whom they are necessary, while avoiding inappropriate assumptions or unnecessary barriers to treatment.

7. Contraindication and Treatment Eligibility

Where pregnancy is contraindicated, the programme must make the treatment decision unambiguous.

The prescriber needs to know what condition must be satisfied before treatment can be initiated and what action is required if pregnancy is suspected or confirmed. Where the product has an exception for situations in which no suitable alternative exists, the programme must preserve that clinical decision pathway rather than turning the general precaution into an absolute prohibition.

EMA's 2023 topiramate referral illustrates this principle: for epilepsy, topiramate should not generally be used during pregnancy unless there is no other suitable treatment, while its use for migraine prevention or weight management is subject to stronger restrictions. The same active substance can therefore require risk controls that depend on indication and clinical necessity. 3

8. Contraception as a Risk-Control Measure

Where contraception is part of the risk-minimisation strategy, the requirement should be explicit about the relevant period and the level of effectiveness expected.

The programme should also address what happens if contraception is interrupted, fails or becomes unsuitable. Counselling should be practical rather than merely stating that contraception is required.

Current national implementation can add operational detail. For example, the French ANSM isotretinoin documentation specifies at least one highly effective method whose effectiveness does not depend on the user, or two complementary user-dependent methods, with contraception beginning at least one month before treatment and continuing for at least one month after treatment. [4]

9. Pregnancy Testing

Pregnancy testing is a control only when its timing and interpretation are connected to a treatment decision.

A programme should define, as applicable:

• the test before initiation;
• the timing relative to treatment and prescription;
• repeat testing during treatment;
• testing after treatment where required;
• who performs or supervises the test;
• how the result is documented; and
• what happens when the result is positive, unavailable or outside the permitted timeframe.

The existence of a testing requirement does not itself establish that the programme is effective. The organisation needs evidence that testing occurs at the clinically relevant decision point and that a result is acted upon.

10. Timing Is Part of the Control

A pregnancy test performed at the wrong time may provide little assurance even if the test itself is technically valid.

This is why national programmes may specify narrow intervals between testing, prescribing and dispensing. France, for example, requires a negative pregnancy test within a defined period before each isotretinoin prescription and limits dispensing to seven days after prescription. [4][5]

Such requirements should be understood as control points in a treatment pathway, not as isolated administrative deadlines.

11. Treatment Initiation

The initiation stage is often the most important point in the control chain because it prevents exposure in an already established pregnancy.

A robust initiation process may require confirmation of treatment eligibility, counselling, contraception, a negative pregnancy test and completion of required documentation before the prescription is issued or dispensed.

The precise sequence depends on the medicinal product and national implementation. The article's later comparison therefore distinguishes the common safety objective from the country-specific operational sequence.

12. During-Treatment Controls

Pregnancy prevention does not end when treatment starts. For products requiring ongoing precautions, the programme should maintain the relevant controls throughout exposure.

Depending on the product, this can include continued contraception, periodic pregnancy testing, repeat counselling, reassessment of the indication, confirmation that treatment remains necessary and renewed documentation.

The control should be proportionate to the duration and nature of exposure. A chronic treatment may need a recurring cycle of checks; a short course may require fewer intervention points.

13. After-Treatment Controls

The risk period may continue after the final dose because the active substance or relevant metabolite may persist or because the product-specific risk-management strategy requires continued prevention.

The post-treatment period should therefore be defined in the applicable product information and risk-minimisation materials. The programme should make the end point visible to the patient and healthcare professional and should specify any required final pregnancy test, contraception period or other action.

14. Counselling Is a Safety Intervention

Counselling should be treated as part of the control mechanism, not as a documentation exercise.

The patient should understand the relevant embryo-fetal risk, what action is required to prevent exposure, when pregnancy testing is required, what to do if contraception fails and whom to contact if pregnancy occurs or is suspected.

The healthcare professional should similarly understand the clinical decision they are expected to make. A signed form is weak evidence if the underlying information was not understood or the required behaviour did not occur.

15. Educational Materials

A PPP can include several audiences and therefore several educational tools.

Typical tools may include:

• healthcare-professional guides;
• patient brochures;
• patient reminder cards;
• checklists;
• acknowledgement or risk-awareness forms;
• treatment or dispensing records; and
• digital information where the national regulatory framework permits it.

The materials should be consistent with the authorised product information and the agreed risk-minimisation objective. They should not create a parallel set of clinical rules.

16. Acknowledgement Forms

An acknowledgement form can document that information was provided and understood where such a mechanism forms part of the agreed programme.

Its value is strongest when it records a meaningful safety decision. For example, it may document that the patient understands the embryo-fetal risk, agrees to specified precautions and knows what to do if pregnancy occurs.

The form should not be treated as proof of actual adherence. It documents a communication or commitment; it does not prove subsequent behaviour.

17. Patient Reminder Cards

A patient card can function as a point-of-care reminder when the patient interacts with another healthcare professional or pharmacist.

For isotretinoin, French ANSM materials require the patient to present the patient card at consultations and dispensing, and the card records elements such as pregnancy-test information and contraception. [5]

This illustrates how a patient-facing tool can become part of a broader control chain rather than simply serving as an educational leaflet.

18. Prescriber Controls

The prescriber is often the first operational gatekeeper.

A PPP may require the prescriber to confirm eligibility, review contraception, order or verify a pregnancy test, complete documentation, provide counselling and issue a prescription within a defined period.

Where treatment is restricted to particular specialists, that restriction may be a separate regulatory control or an element of the national implementation. It should not automatically be described as an EU-wide PPP requirement unless the applicable EU decision or product information establishes it.

19. Pharmacy Controls

The pharmacy can provide a second control point.

Depending on the programme, the pharmacist may need to verify the prescription date, check required documentation, confirm a negative pregnancy-test result or confirm that the dispensing period remains valid.

France provides a clear example for isotretinoin: dispensing is tied to the prescription timeframe and the patient documentation contains information relevant to the required controls. [4][5]

20. Prescription Duration

Limiting the quantity or duration supplied at one time can reduce the interval between clinical review and the next control point.

This is especially useful where the risk-minimisation strategy requires regular pregnancy testing or reassessment.

A short prescription period should therefore be understood as a risk-control mechanism when it is linked to a defined safety objective, rather than simply as an administrative inconvenience.

21. Prescription-to-Dispensing Windows

A prescription may remain valid for only a defined period where timely testing or review is important.

The French isotretinoin programme is an example: the prescription is limited to one month and dispensing must occur within seven days of prescription. [5]

Austria has also historically used a tightly controlled isotretinoin pathway, including 30-day treatment limits and dispensing no more than seven days after prescription. The BASG information further describes physician-supervised pregnancy testing and documentation. 6

These examples demonstrate that similar safety objectives can be operationalised through specific timing controls.

22. Specialist Prescribing

Specialist prescribing can be used where the underlying disease, treatment or reproductive risk requires specialist judgement.

For example, the Austrian BASG has stated that isotretinoin should be prescribed by a physician familiar with systemic retinoids and their risks. France has restricted initial oral isotretinoin prescribing to dermatologists. 6[7]

These are national implementation examples. They should not be generalised into a universal EU rule unless the applicable regulatory text establishes that requirement.

23. Documentation and Traceability

A controlled PPP should allow the organisation and relevant authorities to reconstruct whether the critical steps occurred.

Depending on the programme, evidence may include:

• the approved educational materials;
• version and approval history;
• patient acknowledgement;
• pregnancy-test dates and results;
• contraception counselling records;
• prescription dates and quantities;
• dispensing dates;
• specialist or centre eligibility;
• pregnancy reports and follow-up; and
• effectiveness assessments.

The documentation should be sufficient to demonstrate the operation of the agreed risk-minimisation system without collecting unnecessary data.

24. What Happens if a Control Fails?

A programme should define the response to foreseeable control failures.

Examples include a missed pregnancy test, a positive test, a prescription outside the permitted period, missing documentation, interrupted contraception, suspected pregnancy or treatment continuing despite a failed control.

The response should be clinically appropriate and consistent with the product information and applicable national requirements. The system should make it difficult to proceed silently when a critical control has failed.

25. Pregnancy Occurring During Treatment

A pregnancy during treatment is both a clinical event and a signal about the operation of the risk-minimisation system.

The immediate clinical response should follow the applicable product information and medical judgement. From a pharmacovigilance perspective, the pregnancy should also be handled through the applicable pregnancy-exposure and safety-reporting processes.

At programme level, repeated pregnancies or patterns of preventable exposure should trigger assessment of whether the intervention is being implemented and understood as intended.

26. Effectiveness: Implementation Is Not Enough

Effectiveness evaluation should distinguish several levels:

Programme available
        ↓
Target population reached
        ↓
Controls actually performed
        ↓
Required behaviour occurs
        ↓
Exposure is prevented/reduced
        ↓
Embryo-fetal outcomes improve

Evidence at one level should not automatically be presented as evidence at the next.

For example, distribution of educational materials demonstrates an implementation activity. It does not demonstrate that patients used effective contraception or that pregnancy exposure was prevented.

27. Compliance and Behaviour

Compliance measures can be useful when they directly correspond to the risk-minimisation objective.

Possible measures include the proportion of eligible patients with appropriately timed pregnancy tests, the proportion receiving required counselling, prescription compliance, dispensing compliance or adherence to required contraception measures.

The method should be capable of distinguishing true compliance from documentation alone.

28. Clinical Outcomes

Pregnancy outcomes and congenital outcomes are important but may be too infrequent or multifactorial to serve as the only effectiveness indicator.

Outcome data should therefore normally be interpreted alongside implementation and behavioural measures. A low number of reported pregnancies may reflect effective prevention, low exposure, under-ascertainment or incomplete reporting.

The evaluation design should make these alternative explanations visible.

29. Addendum II and Effectiveness Evaluation

GVP Module XVI Addendum II provides the current EU framework for methods for evaluating the effectiveness of risk-minimisation measures. It became legally effective on 6 August 2024. 1

For a PPP, the evaluation question should be derived from the risk-minimisation objective. If the objective is prevention of pregnancy during exposure, measuring only whether educational material was distributed is insufficient. If the intervention depends on pregnancy testing before dispensing, the evaluation should examine whether that control occurs reliably at the relevant point.

The evaluation should also consider whether other interventions or changes in clinical practice could explain observed changes.

30. The Importance of Baseline Evidence

Where feasible, baseline information can show how the safety behaviour looked before a strengthened programme was introduced.

For isotretinoin, historical French data demonstrated substantial non-compliance with expected prescription and pregnancy-testing requirements. ANSM reported that such evidence contributed to reinforcement of the French programme. [7]

This is a useful lesson for QPPVs: effectiveness evaluation can identify not only whether a programme works, but where the control architecture fails in real clinical use.

31. EU-Level Harmonisation Does Not Mean Identical Workflows

EU-level risk minimisation seeks a common safety objective and appropriate regulatory control. National healthcare systems determine much of the operational environment in which the controls are delivered.

Differences can arise in:

• prescribing classifications;
• specialist access;
• laboratory testing pathways;
• electronic prescribing;
• pharmacy systems;
• reimbursement arrangements;
• patient records;
• national educational materials;
• documentation requirements; and
• the role of national competent authorities.

The existence of these differences does not necessarily mean that the Member States have different safety objectives.

32. Why Member State Comparison Matters

For a centrally authorised product, the MAH may have one EU-level risk-minimisation concept but must operationalise it across multiple healthcare systems.

The pharmacovigilance challenge is to preserve the essential safety controls while ensuring that the national implementation is legally and operationally workable.

This requires a controlled translation from:

EU decision → agreed RMM → national implementation → operational evidence → effectiveness evaluation.

A gap at any interface can weaken the overall programme.

33. Member State Implementation: What Can Vary

The EU risk-minimisation objective should remain stable, but the route by which a patient reaches that objective can differ between Member States.

A useful comparison therefore separates the safety requirement from the implementation mechanism.

For example, a requirement to confirm that pregnancy has been excluded before treatment may be implemented through a laboratory result, a documented clinician assessment, a patient record or a combination of these, depending on the product and national system. The existence of a national difference does not by itself indicate a difference in the underlying EU risk-minimisation requirement.

The same principle applies to prescription and dispensing. A product may have a common EU risk-minimisation measure while national systems determine whether the operational gate is implemented through electronic prescribing, paper documentation, pharmacy verification, specialist prescribing or a combination of controls.

34. France: Isotretinoin as a Layered Control System

France provides a useful example of a mature, highly operationalised PPP for oral isotretinoin.

The French system combines prescriber controls, contraception requirements, pregnancy testing, patient documentation and dispensing controls. ANSM materials specify, among other elements, an initial prescription by a dermatologist, a monthly prescription framework, pregnancy testing close to prescription, and a limited period between prescription and dispensing. The national PPP table also identifies a patient booklet and verification of a negative pregnancy test at dispensing. 4

The historical development is particularly instructive. ANSM reported that monitoring identified insufficient compliance with prescription and dispensing conditions, including missing pregnancy testing before treatment initiation. In response, initial prescribing was reserved to dermatologists from April 2015, while renewal could be performed by another physician. 9

This illustrates an important principle for risk minimisation: effectiveness findings can lead to changes in the control architecture. A PPP is not necessarily static after approval.

35. Austria: Tight Timing and Physician-Supervised Testing

Austria provides another example of a structured isotretinoin pathway.

BASG states that isotretinoin may be prescribed or dispensed to women of childbearing potential only when the conditions of the pregnancy-prevention programme are fulfilled. The national information includes specialist knowledge requirements for prescribers, written and verbal counselling, supervised pregnancy testing, contraception, 30-day treatment limits and dispensing within seven days of prescription. Continuation requires a further supervised and documented pregnancy test. 6

The Austrian example demonstrates how a PPP can operate as a sequence of interdependent gates:

counselling → contraception → supervised testing → prescription → limited dispensing window → repeat testing → continued treatment.

The national detail should not be presented as a universal EU rule. It is an example of how a common teratogenic-risk objective can be translated into a national healthcare pathway.

36. Spain: EU Harmonisation With National Materials

Spain provides a useful example of how national implementation can incorporate EU-level harmonisation while retaining national operational material.

AEMPS reported the PRAC review of oral retinoid pregnancy-prevention measures and described the agreed elements of the programme: risk counselling, contraception, periodic pregnancy testing, risk acknowledgement documentation and educational materials such as a healthcare-professional checklist and patient information card. 10

The Spanish example also illustrates why the active substance, indication and patient population matter. AEMPS noted that oral retinoids did not all require an identical PPP configuration and that some products, such as oral bexarotene and tretinoin, were not considered to require a specific PPP in that review because of their different indications and predominantly hospital-based populations. 10

This supports a broader point: risk minimisation should be product- and population-specific rather than driven solely by the presence of a hazard in the pharmacological class.

37. Cross-Country Comparison: The Control Layers

The following framework is more useful than simply ranking countries by how restrictive their programmes appear to be:

This approach avoids a common analytical error: treating every national procedural difference as a different RMM.

38. Digital and Paper Workflows

Digitalisation can change how a PPP is implemented without changing the safety objective.

An electronic prescribing system may provide automated prompts, prescription-duration controls or links to patient records. A paper system may instead depend on a patient booklet, signed acknowledgement, laboratory report and pharmacist verification.

Digitalisation should not be assumed to improve effectiveness automatically. A poorly designed electronic workflow can create alert fatigue, allow controls to be bypassed or make the required clinical decision less visible. Conversely, a well-designed paper system can provide a strong point-of-care control when its critical steps are consistently followed.

The effectiveness evaluation should therefore assess the control, not merely the technology used to deliver it.

39. Documentation, Data and Proportionality

A PPP needs enough evidence to demonstrate that critical controls operate, but excessive documentation can become a burden that reduces compliance.

The data architecture should be linked to the risk-minimisation objective. If the critical control is a pregnancy test before a prescription, the system should make the test date and relevant result available at the decision point. If the critical control is a dispensing window, the dispensing date must be reconstructable.

The MAH should also distinguish data required for pharmacovigilance and effectiveness evaluation from data collected solely because a local process happens to generate it.

40. Governance of National Implementation

For a centrally authorised product, national implementation should be governed as part of the overall risk-minimisation system.

The MAH should be able to identify:

• the approved EU risk-minimisation objective;
• the national implementation requirements;
• the responsible internal functions;
• the materials in use;
• applicable national approval or notification requirements;
• vendors and service providers;
• implementation status;
• effectiveness data; and
• deviations or corrective actions.

The QPPV should be able to understand whether the national implementation remains consistent with the agreed RMM and whether important deviations create a pharmacovigilance concern.

41. Vendor Oversight

PPP implementation may involve external providers for educational-material distribution, patient support, data capture, call centres, laboratory interfaces or other operational services.

Outsourcing the activity does not outsource the MAH's responsibility for an effective risk-minimisation system.

Vendor oversight should therefore address the critical control rather than merely contract completion. Relevant evidence can include service-level performance, distribution records, quality incidents, data reconciliation, complaints, deviations and corrective actions.

42. Change Control

National programmes can change because of regulatory decisions, healthcare-system changes, digital transformation, product-information changes or findings from effectiveness studies.

Changes should be controlled so that the intended safety objective is preserved. A change to a prescription duration, testing interval, educational document or dispensing workflow can alter the behaviour of the entire programme.

The impact assessment should therefore ask:

1. What safety control is changing?
2. What evidence supports the change?
3. Does the product information or RMP need updating?
4. Does the national material require regulatory review?
5. Are HCPs, pharmacists and patients affected?
6. How will implementation be verified?
7. How will effectiveness be reassessed?

43. Common Failure Modes

Several recurring failure modes can weaken PPPs even when the programme looks complete on paper.

Failure mode 1: Treating education as the programme

Providing a brochure is not equivalent to controlling exposure. If the safety objective depends on testing, contraception or dispensing controls, those elements must be evaluated.

Failure mode 2: Documentation without behaviour

A signed form demonstrates that a process occurred only to the extent that the form is reliable evidence of that process. It does not prove continued adherence.

Failure mode 3: Testing disconnected from the decision point

A technically valid test may provide insufficient assurance if it is performed too early or if its result is not checked before prescribing or dispensing.

Failure mode 4: National divergence without governance

Local adaptation may be necessary, but uncontrolled divergence can create inconsistent implementation of an agreed RMM.

Failure mode 5: Measuring activity instead of effectiveness

Counting distributed materials or completed training records can show implementation. It cannot by itself establish that the risk has been reduced.

Failure mode 6: Failure to learn from exposure cases

Pregnancies during treatment should not automatically be treated as isolated case-processing events. Recurrent patterns can reveal weaknesses in counselling, testing, prescribing, dispensing or patient understanding.

44. Inspection Perspective

A regulator or inspector evaluating a PPP is likely to be interested in whether the system works in practice, not simply whether a programme document exists.

Useful evidence can include:

• the current approved RMM and RMP;
• national implementation documentation;
• version-controlled educational materials;
• distribution records;
• training or communication evidence;
• prescription and dispensing controls;
• pregnancy-test evidence where available and appropriately governed;
• deviations and CAPA;
• complaints and enquiries;
• pregnancy-exposure cases;
• effectiveness studies;
• signal or trend analyses; and
• evidence that findings led to adaptation when necessary.

The central inspection question is often a chain-of-evidence question:

What was the risk? → What control was selected? → Was it implemented? → Did people follow it? → Did it prevent or reduce exposure? → What did the organisation do when evidence showed a weakness?

45. QPPV Practical Review Checklist

For a product with a PPP, a QPPV review can use the following questions:

1. Is the embryo-fetal risk clearly defined?
2. Is the risk-minimisation objective explicit?
3. Is the PPP justified and proportionate?
4. Are all required PPP elements reflected in the agreed materials and processes?
5. Are national differences documented and controlled?
6. Can critical prescribing and dispensing controls be demonstrated?
7. Are pregnancy-testing requirements operationally clear?
8. Are contraception requirements communicated consistently?
9. Are patient and HCP materials current and aligned with product information?
10. Are vendors appropriately overseen?
11. Are implementation indicators distinguished from effectiveness indicators?
12. Are pregnancy exposures analysed for patterns and preventability?
13. Are effectiveness findings reported through the appropriate regulatory channels?
14. Is there evidence that the programme has been adapted when needed?
15. Could an inspector reconstruct the control pathway from the available evidence?

46. A Practical Model for the MAH

A robust PPP can be managed as a closed-loop system:

Safety concern
      ↓
Risk-minimisation objective
      ↓
PPP design
      ↓
EU regulatory agreement
      ↓
National implementation
      ↓
Operational delivery
      ↓
Implementation evidence
      ↓
Behavioural evidence
      ↓
Clinical / exposure outcomes
      ↓
Effectiveness assessment
      ↓
Regulatory review
      ↓
Adaptation
      ↺

The loop matters. A programme should not be considered successful merely because it was designed correctly and deployed across the Member States.

47. Regulatory Interpretation: EU Framework Versus National Practice

The safest way to describe Member State differences is to distinguish three levels of authority:

Level 1 — EU regulatory requirement: the applicable EU marketing authorisation, Commission decision and GVP framework.

Level 2 — National implementation: national competent-authority requirements and healthcare-system arrangements that operationalise the risk-minimisation measures.

Level 3 — Local operational practice: how individual healthcare organisations, prescribers, pharmacies and patients actually execute the controls.

These levels should not be conflated. A national operational requirement may be essential to implementation without being an EU-wide legal requirement. Conversely, an EU-level requirement cannot be treated as optional simply because a national workflow is different.

48. Key Takeaways

• A PPP is a structured risk-minimisation programme, not merely an educational package.
• The current EU framework is GVP Module XVI Addendum I, legally effective from 29 August 2025. 1
• A full PPP is not automatically required for every medicine with an embryo-fetal risk; the decision should consider the risk, indication, treatment population, duration and existing clinical practice.
• Critical controls may include contraindication, counselling, contraception, pregnancy testing, specialist supervision, medication review and packaging reminders. 2
• Timing matters. A control is most useful when it occurs at the clinical decision point it is intended to protect.
• Member States may implement a common safety objective through different prescribing, testing, documentation and dispensing workflows.
• France, Austria and Spain demonstrate how national systems can add operational layers without changing the underlying EU safety objective. 610
• Effectiveness evaluation must distinguish implementation, behaviour, exposure prevention and clinical outcomes.
• Pregnancy exposures can provide evidence about weaknesses in the risk-minimisation system and should be considered in programme evaluation.
• The MAH and QPPV need a clear line of sight from EU RMM design through national implementation to effectiveness evidence.

49. References

1. European Medicines Agency. Good pharmacovigilance practices (GVP) — GVP Module XVI Revision 3 and GVP Module XVI Addendum I. Current EMA GVP framework and legal-effective dates. 1
2. European Medicines Agency. GVP Module XVI Addendum I — Risk minimisation measures for medicinal products with embryo-fetal risks. Legal effective date 29 August 2025. 2
3. European Medicines Agency. Topiramate — referral under Article 31 of Directive 2001/83/EC. EU measures concerning exposure during pregnancy and indication-specific restrictions. 3
4. Agence nationale de sécurité du médicament et des produits de santé (ANSM). Programme de prévention des grossesses — national table of pregnancy-prevention measures, including isotretinoin. 8
5. ANSM. Isotrétinoïne orale et grossesse — actualisation des documents destinés aux professionnels de santé pour la minimisation des risques. National implementation and monitoring measures. 9
6. Bundesamt für Sicherheit im Gesundheitswesen (BASG). Safety information for the use of isotretinoin. Austrian prescribing, testing, contraception and dispensing requirements. 6
7. European Medicines Agency / PRAC. Retinoids — pregnancy-prevention and neuropsychiatric risk review. EU-level harmonisation of oral-retinoid risk-minimisation measures.
8. ANSM. Programme de prévention des grossesses, updated national summary of requirements for medicines including oral isotretinoin. 8
9. ANSM. Isotrétinoïne orale et grossesse — actualisation des documents destinés aux professionnels de santé pour la minimisation des risques, 5 November 2015. 9
10. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Retinoides (acitretina, alitretinoína, isotretinoína): actualización de las medidas para evitar la exposición durante el embarazo, 5 March 2018. 10

50. Regulatory Note

This article explains the EU pharmacovigilance framework and selected national implementation examples for professional education. It does not replace the current product information, RMP, applicable EU decision, national competent-authority requirements or clinical judgement. National requirements and operational arrangements can change; implementation should therefore be checked against current authoritative sources before being used operationally.

Appendix A. Member State Comparison at a Glance

The following comparison is intended as an analytical aid rather than a legal inventory of every national requirement. The examples illustrate how the same broad pregnancy-prevention objective can be translated into different operational controls.

The comparison should be read with the primary national documents. It should not be used as a substitute for the current Summary of Product Characteristics, national prescribing rules or national competent-authority communications.

Appendix B. How to Analyse a New Member State

When evaluating a PPP in another Member State, the following sequence is useful:

1. Identify the EU-level RMM and its exact safety objective.
2. Identify the product-specific RMP and regulatory decision.
3. Check the national competent authority's current implementation material.
4. Determine who can prescribe and under what conditions.
5. Determine how pregnancy testing is performed, recorded and linked to prescribing or dispensing.
6. Determine contraception requirements and the required duration.
7. Determine whether a patient card, acknowledgement form or booklet is used.
8. Determine dispensing restrictions and prescription validity periods.
9. Determine whether the system is electronic, paper-based or hybrid.
10. Determine what evidence exists to demonstrate implementation and effectiveness.

This approach makes it possible to compare systems without assuming that a difference in paperwork represents a difference in regulatory intent.

Appendix C. What the QPPV Should Be Able to Explain

For a product subject to a PPP, the QPPV should be able to explain the programme in one coherent chain:

Why is the risk important?

The embryo-fetal hazard and the circumstances in which exposure can occur should be clearly understood.

Why were these measures selected?

The RMM should be linked to the risk, indication, population and healthcare context.

How does the patient encounter the controls?

The actual patient pathway should be understandable from initiation through treatment and post-treatment follow-up.

How does the pharmacist or dispenser know what to verify?

Where dispensing is a critical control, the relevant verification step should be explicit and demonstrable.

How does the MAH know the programme is operating?

Implementation evidence, deviations, complaints, enquiries, pregnancy exposures and effectiveness data should provide an evidence trail.

How does the organisation respond when the programme underperforms?

The organisation should have a defined route from evidence to regulatory assessment, CAPA or RMM adaptation where appropriate.

Appendix D. Evidence Hierarchy for National Comparisons

Not all sources should be treated as equivalent. For this subject, a practical hierarchy is:

1. European Commission decisions and legally applicable product information.
2. EMA GVP guidance and relevant PRAC/CHMP regulatory conclusions.
3. National competent-authority requirements and official safety communications.
4. Approved national risk-minimisation materials.
5. Published effectiveness studies and post-authorisation studies.
6. Peer-reviewed literature describing implementation.
7. Secondary summaries, professional commentary and other explanatory sources.

A national comparison should preferably rely on levels 1–4 for statements about what is required. Published studies are particularly valuable for understanding whether the required controls actually operate in clinical practice.

Appendix E. Why the Distinction Between Requirement and Effectiveness Matters

A national authority can require a pregnancy test, but that does not establish that every eligible patient receives the test at the correct time. A patient card can be mandatory, but its presence does not demonstrate that counselling was understood. A dispensing restriction can exist in the legal framework, but the real-world effectiveness depends on whether the pharmacy workflow reliably blocks dispensing when a critical condition is absent.

The pharmacovigilance question therefore has two dimensions:

Was the control required and implemented?

and

Did the control achieve the intended safety outcome?

The distinction is central to GVP Module XVI effectiveness evaluation and should remain visible in both MAH governance and regulatory discussions.

Appendix F. Final Practical Framework

For day-to-day QPPV oversight, the entire article can be reduced to six questions:

This model keeps the programme focused on its purpose. The objective is not to maximise the number of forms, tests or restrictions. The objective is to prevent or minimise clinically important embryo-fetal exposure using measures that are justified, operationally reliable, proportionate and capable of being evaluated.

Editorial Scope Note

The Member State examples in this article are deliberately limited. They demonstrate implementation principles rather than attempting to provide an exhaustive catalogue of every national PPP in the European Union. National requirements should be rechecked against current competent-authority and product-specific sources before operational use.

The article should also be read together with the separate QPPV-com article on controlled access and controlled distribution of medicines in the EU in non-pregnancy scenarios. That article addresses controlled-access and distribution mechanisms outside the pregnancy-prevention context and should not be treated as part of the PPP framework described here.